Selegiline is classified as what type of inhibitor?

Selegiline is classified as a selective inhibitor of monoamine oxidase B (MAO-B). This enzyme is primarily responsible for the breakdown of dopamine in the brain. By inhibiting MAO-B, selegiline increases the levels of dopamine, which is particularly beneficial in the treatment of conditions like Parkinson's disease, where dopamine levels are significantly depleted.

The selectivity of selegiline for MAO-B over MAO-A is a critical aspect of its pharmacological profile. This selectivity allows it to enhance dopaminergic activity without significantly affecting the metabolism of other neurotransmitters, such as norepinephrine and serotonin, which are broken down by MAO-A. This reduces the risk of side effects commonly associated with non-selective MAO inhibitors.

In summary, selegiline's classification as a MAO-B selective inhibitor is directly linked to its therapeutic effects in increasing dopamine levels and its targeted action within the central nervous system, making it a valuable treatment option for disorders that involve dopamine deficiency.